GlassScriptPhysician profile
Daniel J Mcgilvray
NPI 1386965234
$7,346.69
in general payments reported to CMS, 2019-2025
38 companies · $2,096 in 2025
The $2,096 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $86.21 · 2021: $29.54 · 2022: $1,281 · 2023: $1,492 · 2024: $1,736 · 2025: $2,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,323.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,214.63 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Glaxosmithkline, LLC. | $1,024.44 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $818.23 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $692.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $635.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.47 | 2022-2025 | Jardiance |
| Pfizer INC. | $351.63 | 2019-2025 | |
| Abbvie INC. | $311.18 | 2021-2025 | |
| Dexcom, INC. | $244.43 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $199.99 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.62 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $138.78 | 2023-2025 | |
| Exact Sciences Corporation | $128.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $104.49 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $86.89 | 2019-2024 | Xarelto |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcgilvray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.